Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) SVP Finbar Larkin sold 1,747 shares of the business’s stock in a transaction dated Monday, May 9th. The stock was sold at an average price of $148.94, for a total value of $260,198.18. Following the sale, the senior vice president now directly owns 19,462 shares of the company’s stock, valued at $2,898,670.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
NASDAQ JAZZ opened at $143.37 on Thursday. The stock has a market capitalization of $8.93 billion, a price-to-earnings ratio of -19.09, a PEG ratio of 1.31 and a beta of 0.79. The stock’s 50 day moving average price is $158.70 and its two-hundred day moving average price is $142.70. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.90 and a current ratio of 3.39. Jazz Pharmaceuticals plc has a 52 week low of $117.64 and a 52 week high of $189.00.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) last released its earnings results on Wednesday, May 4th. The specialty pharmaceutical company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.00 by $0.73. Jazz Pharmaceuticals had a positive return on equity of 22.45% and a negative net margin of 13.63%. The firm had revenue of $813.72 million for the quarter, compared to analysts’ expectations of $853.73 million. During the same quarter in the previous year, the business posted $3.42 EPS. The business’s quarterly revenue was up 33.9% compared to the same quarter last year. On average, equities research analysts forecast that Jazz Pharmaceuticals plc will post 13.55 EPS for the current year.
A number of equities analysts have issued reports on the stock. HC Wainwright raised their price objective on shares of Jazz Pharmaceuticals from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday, March 3rd. Truist Financial lifted their price objective on Jazz Pharmaceuticals from $180.00 to $200.00 in a research note on Thursday, January 20th. BMO Capital Markets cut their target price on Jazz Pharmaceuticals from $202.00 to $187.00 in a research note on Wednesday, March 2nd. Royal Bank of Canada decreased their target price on Jazz Pharmaceuticals from $216.00 to $214.00 and set an “outperform” rating for the company in a research report on Wednesday, March 2nd. Finally, Cowen boosted their target price on Jazz Pharmaceuticals from $200.00 to $225.00 in a research report on Thursday, May 5th. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $206.47.
Jazz Pharmaceuticals Company Profile (Get Rating)
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.
- Get a free copy of the StockNews.com research report on Jazz Pharmaceuticals (JAZZ)
- Corning Stock is a Technology Value Play
- Wolverine Worldwide Is Ready To Rebound
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.